Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 3Cisplatin 3capivasertib 2Gemcitabine 2Carboplatin 2tivozanib 1regorafenib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1encorafenib 1durvalumab 1copanlisib 1cemiplimab 1axicabtagene ciloleucel 1avasopasem manganese 1Valproic Acid 1Thioctic Acid 1Taxes 1Receptors, Interleukin-6 1Radiotherapy 1Radiosurgery 1RNA-Seq 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡